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Abstract
The retroviral phenomenon of superinfection resistance (SIR) defines an interference mechanism
that is established after primary infection, preventing the infected cell from being superinfected by
a similar type of virus. This review describes our present understanding of the underlying
mechanisms of SIR established by three characteristic retroviruses: Murine Leukaemia Virus
(MuLV), Foamy Virus (FV), and Human Immunodeficiency Virus (HIV). In addition, SIR is discussed
with respect to HIV superinfection of humans.
MuLV resistant mice exhibit two genetic resistance traits related to SIR. The cellular Fv4 gene
expresses an Env related protein that establishes resistance against MuLV infection. Another mouse
gene (Fv1) mediates MuLV resistance by expression of a sequence that is distantly related to Gag
and that blocks the viral infection after the reverse transcription step. FVs induce two distinct
mechanisms of superinfection resistance. First, expression of the Env protein results in SIR,
probably by occupancy of the cellular receptors for FV entry. Second, an increase in the
concentration of the viral Bet (Between-env-and-LTR-1-and-2) protein reduces proviral FV gene
expression by inhibition of the transcriptional activator protein Tas (Transactivator of
spumaviruses). In contrast to SIR in FV and MuLV infection, the underlying mechanism of SIR in
HIV-infected cells is poorly understood. CD4 receptor down-modulation, a major characteristic of
HIV-infected cells, has been proposed to be the main mechanism of SIR against HIV, but data have
been contradictory. Several recent studies report the occurrence of HIV superinfection in humans;
an event associated with the generation of recombinant HIV strains and possibly with increased
disease progression. The role of SIR in protecting patients from HIV superinfection has not been
studied so far.
The phenomenon of SIR may also be important in the protection of primates that are vaccinated
with live attenuated simian immunodeficiency virus (SIV) against pathogenic SIV variants. As primate
models of SIV infection closely resemble HIV infection, a better knowledge of SIR-induced
mechanisms could contribute to the development of an HIV vaccine or other antiviral strategies.
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Introduction
Viral entry and replication is a complex process that
involves multiple viral and host proteins. Many host gene
products can interfere with virus infection at the cellular
level (for a review, see: [1]). These proteins are encoded by
variants of essential genes (that can not support viral
infection), or represent true anti-viral factors (gene prod-
ucts whose main role it is to protect the cell from a pro-
ductive virus infection). A special form of virus resistance
is the capacity of cells to prevent a second infection by a
virus that is closely related to the virus that has already
established an infection. In most cases, virus-encoded
proteins are responsible for this phenomenon, which is
termed superinfection resistance (SIR) or viral interfer-
ence. A simple form of SIR is receptor occupancy by viral
Env proteins, preventing the binding of a second virus,
but many additional mechanisms have been described.
Although SIR is not restricted to retroviruses, it has been
studied in depth for this class of viruses. This review deals
with the molecular mechanisms of SIR at the cellular level
in three retrovirus classes: simple retroviruses (here
MuLV), spumaretroviruses (FV), and lentiviruses (HIV).
The mechanisms and clinical consequences of HIV-1
superinfection in patients, which is defined as the reinfec-
tion of an individual with a second heterologous strain of
HIV-1 [2], will also be discussed.
Murine leukaemia virus
In the early 1950's, Gross identified a virus that could
induce leukaemia in mice [3]. This discovery was quickly
followed by the identification of additional leukaemia-
inducing viruses, which led to the definition of the class of
Murine Leukaemia Viruses (MuLVs). Although the list of
MuLV related viruses is still expanding, most MuLVs can
be divided into four classes: ecotropic, amphotropic, pol-
ytropic (sometimes called MCF viruses), and xenotropic.
This classification is based on the type of host cell that is
infected, based on the fact that the 4 classes use 3 different
receptors. Ecotropic MuLVs can only infect murine cells,
whereas polytropic MuLVs infect a broad host range of
mammalian species including mice, albeit with variable
efficiencies. Xenotropic MuLVs can infect many species,
e.g. mink, rabbit, duck and human, but not cells of labo-
ratory mice (reviewed in [4]). The polytropic and xeno-
tropic viruses use the same receptor, Xpr1, also called
Syg1. Polymorphisms in the Xpr1 protein determine the
exact host range of the polytropic and xenotropic MuLVs.
Ecotropic viruses use the amino acid transporter mCAT1
as their receptor, while the receptor for amphotropic
MuLVs is the sodium-dependent phosphate transporter
Pit2.
Cellular factors associated with MuLV restriction, have
been studied extensively, whereby polymorphisms in the
MuLV receptor genes were found to play a major role. Dif-
ferent cell lines were found to express functional variants
of the ecotropic-, polytropic-, and xenotropic-MuLV
receptors, which block infection by certain MuLV strains
[5-7]. Proviral endogenous genes, like the mouse Fv1 and
Fv4 gene products, can mediate restriction of MuLV repli-
cation by SIR associated mechanisms [8,9].
Fv1 mediated resistance to MuLV infection
In 1967 the Fv1 gene was reported to be an important
determinant of cell susceptibility towards MuLV infection
[10]. Two common alleles for the Fv1  gene (Fv1b and
Fv1n)present in prototypical mouse strains of BALB/c and
NIH/Swiss, were found to interfere with certain classes of
MuLVs (reviewed by [1,9]). Cells from NIH/Swiss mice,
which carry the Fv1n allele were resistant to infection with
the so-called B-tropic MuLVs. BALB/c mouse cells, which
carry the Fv1b allele, were resistant to N-tropic MuLVs. In
addition, a third class of MuLVs, the so-called NB tropic
MuLVs, defined strains that can infect Fv1n as well as Fv1b
expressing cells (all reviewed in [9]).
Substitution of defined regions within the N-tropic and B-
tropic MuLV genomes by recombinant DNA cloning
revealed that the Gag gene encoding the capsid protein CA
determines the cell tropism. In particular, a single amino
acid within the CA protein was identified to determine N
or B tropism [11]. Fv1 mediated restriction occurs post-
penetration and at or before integration of the proviral
DNA genome [12], reviewed in [13].
Cloning and sequencing of the Fv1 gene [8] showed that
the Fv1 sequence is similar to the presumptive Gag gene of
human endogenous retrovirus HERV-L (60% identity over
a stretch of 1.3 kb). The Fv1n and Fv1b alleles differ by a few
mutations, and in addition have a length difference of 19
amino acids at the C-terminal end. Gag proteins are
known to interact tightly with each other, which is essen-
tial during virion assembly [1,14]. Possibly, interactions
between the Fv1 Gag-like protein and viral Gag derived
CA are involved in the Fv1 mechanism of resistance (for
reviews, see [1,15,16]). CA has been suggested to act as a
transport signal for the pre-integration complex (PIC) to
facilitate import into the nucleus. The subcellular localiza-
tion of the Fv1 product suggests it may affect virions on
their way to the nucleus [17]. The most straightforward
explanation of Fv1 mediated interference would be bind-
ing of Fv1 to CA in an allele specific way manner that
alters CA binding to the PIC (fig. 1). The PIC could remain
captured in the cytoplasmic compartment and thus not be
able to migrate into the nucleus. However, a direct inter-
action between Fv1 and CA has never been demonstrated,
although crystallographic studies recently suggested that a
potential Fv1 binding domain exists in the MuLV CA [18].
Finally, a direct interaction of Fv1 with the PIC cannot be
excluded, changing its conformation in such a way that itRetrovirology 2005, 2:52 http://www.retrovirology.com/content/2/1/52
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becomes non-functional (fig. 1). However, all mecha-
nisms presented here to explain Fv1 restriction lack solid
experimental evidence, and it should be noted that in the
mouse genome there are hundreds of retroviral elements
more closely related to MuLV than Fv1, and none of these
restricts MuLV replication. A protein named TRIM5alpha
has recently been characterized to restrict HIV-1 by an
Fv1-like mechanism in primate cells. Restriction capabili-
ties of TRIM5alpha vary amongst primates, so that rhesus
monkey TRIM5alpha restricts N-tropic MuLV and HIV-1,
but not B-tropic MuLV, while human TRIM5alpha
restricts N-tropic MuLV, but not B-tropic MuLV or HIV-1
(reviewed in [19]). The ability to restrict HIV-1 is deter-
mined by a single amino acid in the C-terminal SPRY
domain of TRIM5alpha [19]. As for Fv1 restriction of
MuLV, TRIM5alpha targets the HIV-1 CA protein. Several
mechanisms have been proposed for TRIM5alpha restric-
tion, including binding and trapping of incoming virus,
interference with uncoating, inhibition of SUMOylation
(and thereby interfere with intracellular trafficking of the
PIC), and targeting the incoming particle for proteasomal
degradation whereby TRIM5alpha transfers the ubiquitin
molecules to CA (reviewed in [1,9]). Elucidating the way
by which TRIM5alpha restricts retroviruses might also
shed light upon the mechanism of Fv1 restriction.
Fv4 mediated resistance to MuLV infection
In 1975, Suzuki described the discovery of a new resist-
ance gene, Fv4, in the G strain of laboratory mice [20,21].
The Fv4 gene was also identified in Asian wild mouse spe-
cies [22]. Genetic mapping studies located the Fv4 gene on
chromosome 12 [23]. There are two alleles at the Fv4
locus: the Fv4r resistance allele is dominant [20,21]. A first
clue about the nature of the Fv4 gene came with the iden-
tification of MuLV Env related proteins in Fv4 resistant
cell lines [24], which suggested an Env-like sequence for
the Fv4 gene. Using an Env-specific probe, a 5.2 kb frag-
ment of the Fv4r was cloned that contained part of the Pol
gene, the entire MuLV Env region and the 3' long-terminal
repeat (LTR) of an ecotropic MuLV [25,26]. Sequence
analysis revealed that Fv4 Env encodes a surface (SU) and
transmembrane (TM) Env domain that closely resembled
(>90%) the homologous Env sequences in the unusual
ecotropic MuLVs found in Asian wild mice [22]. Trans-
genic mice carrying the Fv4 gene showed complete resist-
ance to ecotropic MuLV infection [27]. Moreover,
transplantation of a certain percentage of Fv4 resistant
bone marrow cells into the bone marrow of Fv4 suscepti-
ble mice strains induced full resistance against MuLV
infection [28]. Although Fv4 mediated resistance has been
demonstrated in different experimental systems, the
underlying molecular mechanism remains unclear. As
described earlier, Env-receptor interactions mediate retro-
viral entry into the target cell. Therefore, Fv4r mediated
resistance has been suggested to rely on Fv4 Env binding
to the MuLV receptor, which prevents exogenous MuLV
infection. Substitution of the complete Fv4r Env gene in
MuLV clones abrogated viral entry, indicating that the
protein is defective [29]. The defect was attributed to a sin-
gle amino acid substitution in the fusion peptide of the
Fv4r Env protein, which when artificially introduced into
an MuLV clone led to an Env protein that was able to bind
to the cellular receptor, and was incorporated into virus
particles at normal levels, but was incapable of promoting
fusion and viral entry [30].
Fv4 and mCAT1 interactions
Sequence analysis of the ecotropic MuLV receptor showed
it to be a cationic type 1 amino acid transporter (mCAT1)
[31,32]. Comparable expression patterns of mCAT1
mRNA have been described for different tissues of Fv4r
congenic MuLV-resistant (C4W = BALB/c-Fv-4Wr) and -
susceptible (C3H/HeMsNrs and C56BL/6) mice strains.
However, recombinant F-SU/GFP, consisting of the SU
domain of Friend MuLV and the GFP protein, was unable
to stain most mCAT1 mRNA expressing tissues of the C4W
(Fv4r) mice strain [33], suggesting that either an intracel-
lular downregulation of the receptor has occurred, or that
the receptor is blocked at the cell surface by the Fv4 gene
product (fig. 2).
Altogether, these data strongly suggest that Fv4r interferes
with MuLV infection by masking of the MuLV receptor
through binding of Fv4 Env. Two other mouse interfer-
ence genes, named Rmcf1 and Rmcf2, also cause MuLV
resistance by Fv4-related interference mechanisms
[34,35]. Crosses between an Rmcf1 resistant mouse strain
and an Rmcf1 lacking mouse strain revealed that inherit-
ance of Rmcf1 resistance correlated with the inheritance of
an endogenous MCF virus Env gene. The Rmcf2 gene also
encodes an Env glycoprotein, and its expression blocks
infection by polytropic MuLVs [35].
Foamy viruses
In 1950 a new type of retrovirus was isolated from cell cul-
tures derived from monkey kidneys. Foamy viruses (FV)
were named after the characteristic foam-like effect they
induce in cell culture. FVs are considered to be harmless in
experimentally infected animals. The various unique fea-
tures of FVs concerning their replication led in 2002 to the
establishment of a new, distinct retroviral subfamily: the
spumaretrovirinae (reviewed in [36]).
The genomic structure of FVs indicates that these viruses
belong to the more complex retroviruses. The FV genome
transcribes, besides Gag, Pol and Env, two major mRNA's
from an internal promoter near the 3'end of the genome
(reviewed in [36]): a DNA binding protein called Transac-
tivator of spumaviruses (Tas), and the 60 kDA Bet protein.
Tas is involved in the switch from latent to lytic virusRetrovirology 2005, 2:52 http://www.retrovirology.com/content/2/1/52
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replication, while Bet has a negative regulatory effect upon
the internal promoter [37,38]. Furthermore, Bet can
inhibit the APOBEC3 family of antiretroviral proteins
[39], and mediates SIR [40].
FV Env mediated SIR
As retrovirus entry depends on the interaction of the SU
domain of Env with the target receptor, down-regulation
of such a receptor would be a plausible mechanism for
SIR. To date no receptor has been identified for FV. It has
been proposed that a pH-dependent fusion process medi-
ates foamy virus entry [41]. To investigate FV superinfec-
tion, Moebes and colleagues [42] tested whether
overexpression of the FV Env protein induced SIR by
downregulation of the putative receptor. Indeed, BHK-21
cell lines containing a stably transfected Env gene were
completely resistant to infection with FV vectors that use
FV Env for entry.
Deletion analysis of the FV Env protein showed that sev-
eral properties of Env are needed to induce SIR: mem-
brane anchorage of Env extracellular domains, efficient
cell surface transport of the Env protein, and correct
processing of the Env subunits [43]. So, in contrast to
MuLV Env, secretion of FV Env is not sufficient to induce
SIR.
A recombinant FV SU-Ig protein and FV Env expressing
cell lines were constructed to study FV Env binding to the
surface of target cells [44]. The receptor for FV is still unde-
termined, and it is possible that general features on the
membrane surface, like for example glycolipids, mediate
FV entry. This would explain the broad infection range of
FV on mammalian and non-mammalian cells [45]. How-
ever, the binding experiments suggested that SIR by FV
Env is similar to SIR by other retroviruses, whereby high
expression of FV Env in stably transfected cell lines led to
a complete resistance to FV SU-Ig binding and FV permis-
siveness, and low expression of FV Env led to a decreased
susceptibility to infection and a lowered FV SU-Ig binding
[44].
Concluding, the expression of FV Env proteins establishes
resistance against FV superinfection. Moreover, FV Env
proteins induce SIR at the cell surface, which suggests
down-regulation of cell surface FV entry mediators. How-
ever, the exact underlying mechanism of SIR remains
unclear.
Bet mediated resistance to FV superinfection
Chronically infected FV cells, which are characterized by
reduced production of Tas, are found to express predomi-
nately ∆HFV, a distinct proviral form of FV [46,47]. A per-
sistent but latent infection is common in FV infected
animals (reviewed in [48]). ∆HFV contains a 301-bp dele-
tion in the Tas gene, which is spliced out from the prege-
nomic RNA [46]. Interestingly, ∆HFV seemed to interfere
with FV infection [38]. This interference strongly corre-
lated with the number of integrated ∆HFV copies [38].
∆HFV constructs with a defective Bet gene were unable to
interfere with FV infection [38], suggesting that Bet is
involved in SIR. Normally, ∆HFV transfected cells contain
stable levels of Bet mRNA and protein, and Bet is the
major viral protein expressed in chronically infected cells
[38].
The establishment of a Bet-expressing cell line confirmed
a Bet-mediated induction of SIR [40]. Interestingly, Bet-
induced SIR is unlikely to be mediated by Env-directed
down-regulation of the FV receptor, as no Env mRNA or
proteins were detected during the early phase of ∆HFV
interference with FV infection [38]. In addition, Bet+ cells
did not prevent infection by a GFP-MuLV vector contain-
ing a ∆HFV envelope construct whereby the cytoplasmic
tail of the transmembrane part is derived from MuLV [40].
As this vector contains the HFV envelope surface and TM
domains, it must use the FV receptor to gain access to the
Bet+ cells.
Infection of Bet+ and Bet- cells by FV resulted in 3–4 fold
lower titres in the Bet+ cells [40]. As proviral DNA was able
to integrate into the host genome, Bet possibly interferes
with FV replication during transcription of the provirus,
although the lower levels of FV in Bet+ cells could suggest
an additional effect upon viral entry. Foamy viruses con-
tain an internal promoter that drives transcription of Bet
and Tas mRNA (reviewed in [36]). The transactivator Tas
activates both the LTR and internal promoters by direct
binding [37]. Bet and Tas are produced from overlapping
reading frames and mediate opposite effects on FV repli-
cation (fig. 3). Cell lines chronically infected with FV con-
tain abundant levels of the negative regulator Bet, low
levels of structural proteins and of the transactivator Tas,
and a high ∆FV load [37,38]. Increasing the level of Tas by
transfecting latently infected cells with a Tas expression
vector triggered FV replication and cell lysis [37]. Thus, Bet
reduces FV replication by inhibition of Tas expression,
which in turn reduces internal promoter activity. The exact
mechanism by which Bet inhibits Tas expression is not
clear. Bet protein could stimulate splicing of its own
mRNA, which consequently would alter Tas RNA levels.
Other possibilities are Bet-mediated inhibition of Tas
RNA transport or decreased stability of Tas RNA. It seems
unlikely that Bet prevents Tas expression by stimulation of
promyelocytic leukaemia protein (PML), the only known
inhibitor of Tas [49], as significant amounts of PML were
unable to prevent FV replication [50].Retrovirology 2005, 2:52 http://www.retrovirology.com/content/2/1/52
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HIV superinfection resistance
To date an estimated 40 million people worldwide are
infected with the Human Immunodeficiency Virus (HIV),
classified as a lentivirus within the class of retroviruses.
HIV is associated with the development of Acquired
Immune Deficiency Syndrome (AIDS). Two main virus
types exist, HIV-1 and HIV-2, of which HIV-1 infection is
the most important cause of AIDS.
Like all other retroviruses, the HIV virion contains two
copies of an RNA genome that is encapsulated by CA and
Env proteins. The Env glycoproteins gp120 and gp41
mediate viral entry by interacting with CD4 molecules on
susceptible cells. The CD4 receptor is a type 1 transmem-
brane glycoprotein and is mainly found on primary T lym-
phocytes, dendritic cells and macrophages. Interaction of
gp120 with CD4 induces conformational changes in the
Env protein structure, which enables Env to interact with
a coreceptor, such as the CCR5 or CXCR4 chemokine
receptor, which leads to HIV entry into the target cell
(reviewed in [51]). Several host factors have been identi-
fied that interfere with early steps during entry or replica-
tion of HIV-1, e.g. APOBEC3G/CEM15, Lv1, Lv2, and
TRIM5alpha (for a review, see: [16]). Additional mecha-
nisms by which an initial virus can inhibit entry or repli-
cation of a second virus will be discussed below.
Since the identification of the AIDS virus, various strate-
gies have been proposed to prevent the spread of HIV
infection. The underlying mechanisms of SIR in HIV-
infected cells are of particular interest for the development
of novel antiviral approaches related to SIR. However, as
a caveat, we note that several studies describe the occur-
rence of HIV superinfection in patients. The next sections
will describe the current understanding of the underlying
mechanisms of SIR by HIV-1.
CD4-mediated resistance to HIV superinfection
One of the major characteristics of HIV-infected cells is
down-modulation of the CD4 receptor [52-54]. To date
three viral HIV proteins; Vpu, Env, and Nef have been
identified that mediate CD4 down-regulation by distinct
mechanisms (reviewed in [55,56]), indicating the impor-
tance of CD4 down-regulation for HIV infection. As recep-
tor down-modulation is a simple way of preventing a
second viral infection, and a method that is successfully
used by other retroviruses, CD4 down-modulation was
initially assumed to be the main SIR mechanism in HIV
infection.
All primate lentiviruses, HIV-1, HIV-2 and Simian Immu-
nodeficiency Virus (SIV), encode the Nef protein
(reviewed in [55]). Nef binds directly to a di-leucine-like
motif in the cytoplasmic domain of CD4. Nef is able to
bind different members of the adaptor proteins (AP-1, AP-
2, AP-3 and AP-4), which contain distinct transport sig-
nals. Simultaneous binding of Nef to CD4 and AP-2 at the
cell surface induces endocytosis of CD4. In addition, Nef
binding of AP-1 and AP-3 in the trans-Golgi network may
mediate trafficking of newly synthesized CD4 directly to
lysosomes. Stable transfection of the SIV Nef gene in a
CD4+ T cell line reduced cell surface-expression of CD4,
and rendered the cells resistant to subsequent HIV-1 infec-
tion [57]. As HIV-1 transcription was not inhibited in
these cells, the authors speculate that the inhibition of
superinfection in this model system is due to Nef-induced
CD4 down-modulation. Besides, a clonal HIV-1 contain-
ing T cell line with down- regulated CD4 expression is also
resistant to HIV-2 superinfection [54]. HIV-2 infected cells
do not seem to resist subsequent HIV-1 infection, which
may be explained by the inability of HIV-2 to induce CD4
down-modulation.
In contrast to Nef, Env and Vpu mediate CD4 down-mod-
ulation by preventing the intracellular transport of newly
synthesised CD4 molecules (reviewed in [56]). Binding of
CD4 by the Env precursor protein gp160 in the endoplas-
matic reticulum (ER) triggers the formation of aggregates,
which block further CD4 transport to the cell surface. In
addition, Vpu mediates CD4 down-modulation by direct-
ing newly synthesised CD4 to proteosomes for degrada-
tion. Among the immunodeficiency viruses, Vpu is
encoded nearly exclusively by HIV-1. Vpu has been sug-
gested to redirect CD4 trafficking by acting as an adaptor
between CD4 and the h-βTrCP protein that is a key con-
nector in the ubiquitin-mediated proteolysis machinery.
Restriction of Vpu mediated CD4 down-modulation
either by inhibition of the proteosome activity or muta-
tion of putative ubiquitination sites in the CD4 cytoplas-
mic domain supports this hypothesis.
The most important physiological purpose of CD4 down-
modulation is likely not to resist superinfection, but
rather to increase viral replication and to promote the
release of progeny virions [57,58]. Reduction of CD4 cell
surface-expression results in particles with less CD4 and
more Env molecules, which probably eases their release
from the cell. When using HIV-1 variants with different
coreceptor usage obtained from patients, it was found that
down-modulation of CD4 was not associated with CCR5-
using viruses that are present early in infection, but were
characteristic of CXCR4- or CXCR4/CCR5-using viruses
that are mostly seen later in infection during the onset of
AIDS [59]. In line with this, Lusso et al. [60] found that a
macrophage-tropic, non-cytopathic strain of HIV-1 that
did not down-regulate CD4, did also not resist subse-
quent superinfection with a cytopathic HIV-1 strain in a
CD4+ T-cell clone (PM1) susceptible to a wide variety of
HIV isolates. Furthermore, Nef-genes from AIDS patients
were far more efficient in down-regulating CD4 than Nef-Retrovirology 2005, 2:52 http://www.retrovirology.com/content/2/1/52
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alleles from asymptomatic patients [58]. Together, these
results raised a question whether CD4 down-modulation
in vivo is a significant cause of SIR in HIV-1 infection.
Additional questions about the relevance of CD4 down-
regulation come from analysis of the kinetics of CD4
down-modulation in HIV-infected T cells. CD4 down-reg-
ulation starts two days after infection and just a few hours
before the cells are committed to die (reviewed in [56]).
This leaves only a small time span in which CD4 down-
modulation of infected transformed T cell lines may inter-
fere with HIV superinfection. Moreover, down-modula-
tion of CD4 in primary T-lymphocytes occurs even later.
The half-life of HIV-infected cells in patients has been esti-
mated at 1 to 2 days. Volsky and colleagues [61] demon-
strated SIR to be established relatively early between 4 and
24 hrs after primary HIV-infection. Thus, the kinetics of
CD4 down-modulation would imply that the established
resistance to HIV-1 superinfection is not mediated by CD4
down-modulation. Indeed, HIV-1 SIR has been demon-
strated to occur independently of CD4 down-modulation
as will be discussed hereafter.
Co-receptor down-regulation could be an alternative SIR
mechanism. However, down-regulation of CXCR4 was
not observed in culture, and although chronic infection
with CCR5-using viruses abrogated CCR5 expression, the
effect on superinfection was not tested [59]. A single study
suggested that CCR5 down-modulation in an HIV-2
infected cohort of Senegalese women protected them
from HIV-1 superinfection [62].
CD4-independent mechanisms contributing to HIV SIR
A few studies have shown cellular resistance to HIV super-
infection by mechanisms unrelated to CD4 (reviewed in
[63,64]). Volsky and colleagues [61] demonstrated SIR in
HIV-1-infected T cells that still expressed substantial levels
of CD4. Moreover, non-functional HIV-1 mutants and
HIV-1 mutants that could only bind CD4, but not enter
the T-cells, did not restrict superinfection of HIV-1 in
these cells. The mechanism was HIV-1 specific, as the cells
could be infected by other (retro)viruses, indicating that
the results could not be explained by a general block of
virus replication. HIV-1 mutants that encode inactive Vpu,
Vpr and Nef genes were fully active in SIR, ruling out these
genes as contributing to HIV SIR.
Another study demonstrated CD4 independent SIR mech-
anisms in cells infected with a non-producer HIV mutant
[65]. CD4 down-modulation in these F12-HIV-infected
cells did not change their susceptibility to a challenge HIV
strain. However, SIR was established by inhibiting the rep-
lication of the superinfecting HIV strain. An additional
study evaluated SIR in cells transfected with distinct vec-
tors containing a particular HIV protein [66]. The F12-HIV
genes Gag, Vif and Nef were all found to alter replication
of the superinfecting HIV-1 strain. Moreover, expression
of Nef established complete resistance against the chal-
lenge by inhibiting HIV-1 replication at a late stage. Nef
mediated inhibition of viral replication has been associ-
ated with interference of Gag processing by preventing the
cleavage of the p41 Gag precursor protein into p17 (MA)
and p24 (CA) [67]. Moreover, the disturbed processing of
Gag has been correlated with an altered sub-cellular distri-
bution of F12-Nef compared to the wild-type Nef protein.
CD8 T-cells and HIV superinfection resistance
In animals, antiviral effects, either to the initial or to a sec-
ond viral infection, are in large mediated by the immune
system, making superinfections of animals greatly differ-
ent from SIR in cells. A 100% effective SIR mechanism
could prevent superinfection of a given cell in an animal,
but a second virus could infect another, non-infected cell,
leading to superinfection of the animal, but not to super-
infection of the already infected cell. Neutralizing anti-
bodies restrict re-infection of cells from seropositive
donors in culture [68], and cytokines induced by the first
viral infection can have a negative effect on subsequent
infections [69]. An important immune-mediated inhibi-
tion of viral replication is exerted by non-cytotoxic CD8+
T-cells. These cells belong to the innate immune system
and were found to suppress HIV-1 replication in CD4+ T-
cells by a non-cytotoxic mechanism mediated by a soluble
antiviral factor, provisionally named CAF [70] (for
reviews see: [71-73]). Until now, the identity of CAF, short
for CD8+-cell antiviral factor, has not been resolved, but
it suppresses transcription of viral RNA [74,75], is found
in both healthy persons and in asymptomatic HIV-1
infected patients [76], can be inhibited by protease inhib-
itors [77], and strongly suppresses HIV-1/HIV-2 superin-
fection in culture [78], and as such is included in this
review. The mechanism is not virus or species specific, and
is also operational in vivo. It has been found in HIV-2
infected baboons [79], and in FIV (feline immunodefi-
ciency virus)-infected cats [80]. HIV-2 infected PBMC
from pig-tailed macaques, however, can be superinfected
with another strain of HIV-2 in vitro in the presence of
CD8+ T-cells [81]. Furthermore, 80–100% of chimpan-
zees experimentally infected with HIV-1 could be superin-
fected after 8 to 64 months with a same or different viral
subtype despite a fully functional immune system
(reviewed in [82]).
Besides CAF as soluble factor, the studies by Locher et al.
[79] and Chun et al. [83] suggest that contact between
CD4+ and CD8+ cells is important for inhibiting viral rep-
lication, including HIV-1 superinfection. During disease
progression, the anti-HIV effect of the CD8 T-cells is grad-
ually lost [76,84], as is their ability to suppress superinfec-
tion [78], which is probably due to a functionalRetrovirology 2005, 2:52 http://www.retrovirology.com/content/2/1/52
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impairment of the (HIV-specific) CD8+ cells in the AIDS
phase [85].
HIV superinfection in vivo
HIV-1 can be classified into three distinct groups based on
genome sequences; M (major group), O (outlier group)
and N (non-M/non-O group), which can be further sub-
divided into different subtypes (reviewed in [86]). The M
group represent the major HIV-1 strains responsible for
the worldwide spread of AIDS, and encompasses at least
10 distinct subtypes. The O group represents a minority of
the HIV-1 strains and is found in approximately 2–5% of
HIV-1-infected individuals in West and Central Africa.
In the late 80's and early 90's of the last century, a number
of primate models demonstrated the possibility of HIV-1
superinfection in vivo, a phenomenon that was later also
described in humans (reviewed in [2]). Several papers
report HIV-1 dual infections as co-infections and not
superinfections, as successive infection with two different
viruses is often difficult to prove due to limited sampling.
It is likely that in a patient, a second virus infects cells that
are not infected by the resident virus. Superinfection of
HIV-1 in humans can be classified as intra-subtype-, inter-
subtype- or inter-strain (M/O)- superinfection. Three
studies reported HIV-1 group B-infected individuals to be
infected by a distinct subtype B virus [87-89]. HIV-1 sub-
type B superinfection occurred in two cases in the absence
of any antiviral drugs, and in one case during treatment
interruptions. A multiple drug-resistant virus was the ini-
tial infecting clade B virus in two patients. In all cases, the
appearance of the second virus resulted in a decline in
CD4+ T-cell counts and an increase in HIV-1 plasma lev-
els. Three cases of HIV-1 superinfection with different sub-
types of HIV-1 group M, all with subtype B and
CRF01_AE, have been reported so far (reviewed in [2]). A
HIV-1 triple infection was recently reported in a Dutch
patient practising unsafe sex [90]. One year after the orig-
inal infection with a subtype B strain, this patient was
superinfected with a second subtype B strain, and again a
year later another superinfection occurred, this time with
subtype CRF01_AE. Only the second superinfection
resulted in an increase in viral plasma load and a decrease
in CD4+- cell counts and was accompanied by flu-like
symptoms. Another triply infected individual, this time
from Tanzania, was infected with a subtype C strain and
two divergent subtype A strains [91]. However, in this
patient it was not clear whether the triple infection was the
result of superinfection or of simultaneous infection.
Thus, different HIV-1 group M subtypes are able to estab-
lish superinfection resulting in all cases in increased dis-
ease progression. Several studies have identified
individuals who are dually infected with two distinct HIV-
1 strains. In 1999, a dual M/O infected Cameroonian
patient was identified [92], followed by five additional M/
O dually infected individuals [93,94], and one O/M
superinfected patient [95]. Apart from these anecdotal
reports, several studies have attempted to study superin-
fection rates in cohorts of highly exposed individuals. In
two cohorts, and in one study involving 14 HIV-serocon-
cordant couples, no evidence for superinfection was
found [96-98], but several other studies report significant
rates of superinfection in recently infected individuals.
Three cohorts of intravenous drug users showed a 2.5–5%
incidence of HIV-1 superinfection [99-101]. A 19% inci-
dence was scored in a cohort of female sex workers within
three months of primary infection [102]. However, the
latter superinfections were transient, and no evidence of
dual infection was seen after 24 months of follow-up
[102]. A transient subtype B superinfection was also
apparent in one of the intravenous drug users [99]. The
incidence of HIV-1 superinfection is probably increasing
as more people become infected, as this enhances the
chance of meeting an already infected partner.
Viral recombinants, which are an indicator of superinfec-
tion on a cellular level, have been reported from the
beginning of the epidemic. It has been suggested that
recombination is an important viral evolutionary strategy
for HIV, and may be considered a key aspect of viral repro-
duction, so-called "viral sex" [103]. Recombinants pro-
vide strong evidence that cellular SIR is not absolute, i.e.
in patients some cells are superinfected at some
frequency.
The occurrence of HIV-1 superinfection in humans raises
questions about the possibility of developing an effective
HIV-1 vaccine, both because of the obvious lack of protec-
tion of an already infected individual to a second infec-
tion (reviewed in: [82,104]). Nowadays, at least 15
circulating recombinant forms have been recognized
within HIV-1 group M [2], and many more exist in indi-
vidual patients. Fang and colleagues [105] described an A/
C recombinant HIV-1 virus that was formed in a female
sex worker, who was superinfected with HIV-1 subtype C
after primary infection with HIV-1 subtype A. The devel-
opment of new HIV-1 recombinants could also quickly
alter various properties of HIV-1, such as cell tropism,
viral pathogenicity, antiretroviral drug susceptibility and
disease progression.
The studies described here clearly demonstrated HIV-1
superinfection in humans both with different HIV-1
strains and with closely related HIV-1 subtypes. In an
asymptomatic patient, a large reservoir of uninfected cells
is available for infection by a second virus, as only 1:2,500
to 1:100,000 CD4 cells are estimated to be infected by
HIV [106,107]. During disease progression, substantially
more virus is produced, and more CD4+ cells becomeRetrovirology 2005, 2:52 http://www.retrovirology.com/content/2/1/52
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infected [107]. Thus, in the later stages of HIV infection,
when both viruses produce a significant amount of prog-
eny, uninfected cells can become dually infected with
both virus strains, enabling the formation of recombinant
forms. In other cells of the same organism, SIR might be
operational and prevent a second infection. Indeed, in
splenocytes of two HIV patients, an average of three to
four HIV-1 proviruses was found [108]. Sequence analysis
showed that proviruses in a single cell were often geneti-
cally distinct, and gave rise to recombinants [108].
Discussion
Are mechanisms of SIR comparable among retroviruses?
Apart from the immune response, other cellular mecha-
nisms are operational to prevent superinfection of cells by
a second, related virus. SIR mechanisms from three retro-
viruses, from simple to complex, have been reviewed here.
Are there any general lessons to be learned from these
studies? For MuLV, a simple retrovirus that contains no
accessory genes, SIR mechanisms have been deduced for
two viral genes, Gag and Env that were captured by the
host. Expression of these genes prevents infection of the
cells by MuLV, probably by interfering with viral entry and
reverse transcription. For FV, a more complex virus, the
accessory gene-encoded protein Bet induces SIR, as did
expression of the Env protein. The situation with HIV, the
most complex retrovirus of the three, is less clear. Receptor
down-modulation occurs late in infection, induced either
by the Env, Vpu or Nef proteins, but this does not seem to
be the principal SIR mechanism. It may instead be more
important for efficient production of virions. HIV-spe-
cific, CD4-independent superinfection resistance has
been described that occurs early after initial infection, but
the proteins involved have not been identified conclu-
sively. One study ruled out Vpu, Vpr and Nef, while
another study showed that expression of Nef  induced
complete resistance against a challenging HIV strain, pos-
sibly by interfering with Gag processing. In the latter
study, Gag and Vif expression was also found to interfere
with viral replication.
Thus, no general picture regarding SIR mechanisms
emerges from the study of these retroviruses. Although
Env expression is often found to interfere with infection,
simply by occupying the viral receptor, the accessory pro-
teins play a more prominent role in complex retroviruses.
Especially for HIV, the mechanism is far from clear, and
multiple viral proteins may be involved. In no instances
have specific host factors been identified.
SIR and clinical HIV superinfection
The most important questions regarding HIV superinfec-
tions in a clinical sense are how often do they occur, and
what are the consequences? Also, is in vitro research into
SIR translatable into clinical practice?
Concerning the first question, if recombination is a valid
viral evolutionary strategy, more HIV superinfections may
occur than we detect. Two papers report transient superin-
fections, where after a short time of proven double infec-
tion in asymptomatic patients, only a single virus is
detected later on [99,102]. If transient superinfections are
common, they add to our underestimation of the
phenomenon.
Ideally, superinfections should be prevented by the phe-
nomenon of SIR as well as by the immune system. How-
ever, SIR cannot protect every target cell in an organism,
as only infected cells can display SIR. Neutralizing anti-
bodies and/or virus-specific CD8+ cell response against
the first virus do, unfortunately, not seem to prevent HIV
superinfection [2].
In studies of vaccinated macaques, a window period for
superinfection was found. Monkeys challenged with a sec-
ond SIV strain later than 10 days [109] or 4 weeks [81]
Schematic of three possible interference mechanisms medi- ated by Fv1 expression Figure 1
Schematic of three possible interference mecha-
nisms mediated by Fv1 expression. Although the mech-
anism of Fv1 interference is still poorly understood and firm 
experimental evidence is lacking, several likely routes can be 
envisaged. Route A depicts the binding of Fv1 to CA, thereby 
restricting CA participation in the integration of the pre-inte-
gration complex (PIC) of MuLV DNA. In favour of this 
model, crystallographic studies recently suggested that a 
potential Fv1 binding domain exists in the MuLV CA [18]. 
Alternatively, if yet undetermined CA helper factors (CAhf) 
are needed during CA mediated integration of the PIC; bind-
ing of Fv1 to CAhf would prevent CAhf to assist CA during 
integration of the PIC (route B). A third possible route 
would involve direct binding of Fv1 to the PIC, thereby 
changing its conformation, and restricting it from further 
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after the first SIV infection, resisted superinfection,
whereas all earlier challenges resulted in superinfection.
In studies where the animals were challenged much later
(15–122 weeks), all monkeys except one in the 15-week
challenge group were resistant to superinfection, irrespec-
tive of the infection route [110-113]. However, in humans
it is questionable whether a such a window period is oper-
ational, as for example in the study of Ramos et al. [114],
one subject became infected 3–6 weeks after the initial
infection, while a second patient was superinfected 5–9
months after seroconversion. Also, in the study by Yerly et
al.  [99], superinfections occurred years after the initial
infection. In the chronic phase of infection, only a small
fraction of susceptible cells are infected and many remain
available to host a second virus. During disease progres-
sion, as CD4+ cells and the CD4 levels of infected cells
decline, the patient should become less susceptible to
superinfection, also because pathologic symptoms
decrease the risk of re-exposure. Possibly, every patient is
susceptible to HIV superinfection at some time, with the
risk of re-exposure being the main limiting factor. It could
also be that superinfected patients have some molecular
defect that allows them to establish a second productive
infection, or that the primary HIV strain is defective in SIR
induction. That would imply that most HIV-infected indi-
viduals possess some resistance mechanism, and that the
few identified HIV superinfected individuals among the
large groups of HIV-infected participants are exceptions.
Schematic of Fv4 mediated interference of MuLV infection Figure 2
Schematic of Fv4 mediated interference of MuLV infection. Fv4 expression results in sustained levels of Fv4 Env pro-
teins in the cytoplasm. Binding of the mCAT1 receptor by Fv4 Env proteins, either in the cytoplasm or at the cell surface (the 
exact location of interaction is unresolved, which is represented by question marks), prevents MuLV Env to interact with 
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However, in chronically infected patients, a productive
HIV superinfection could be regarded as an opportunistic
infection that warrants the diagnosis of AIDS. Here it is
important to note that HIV-1 superinfection is associated
with an increased viral load, a decrease in CD4+ T cell
count, and increased disease progression in most cases. A
shorter time to death was seen in HIV-2 dually infected
monkeys compared to animals that resisted superinfec-
tion [81]. So, a productive HIV superinfection should be
considered as a marker of disease progression and the start
of the AIDS phase.
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